Besides, for the treatment of vemurafenib-resistant melanoma, Fu et al. developed a nanoliposome loaded with protein kinase C inhibitor, palmitoyl-dl-carnitine chloride (PC), and BRD4-targeting PROTAC as a novel approach to Inhibit angiogenesis in BRAF-mutated malignant melanoma [104]. Here, BRD4 is linked to melanoma.